Brokerages Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Price Target at $18.75

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $18.75.

A number of research firms have commented on LXEO. JPMorgan Chase & Co. reduced their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 10th. Finally, Chardan Capital reiterated a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research report on Monday, May 11th.

Lexeo Therapeutics Trading Down 3.0%

NASDAQ:LXEO opened at $4.55 on Thursday. Lexeo Therapeutics has a 1 year low of $3.60 and a 1 year high of $10.99. The firm has a 50 day moving average of $4.81 and a 200-day moving average of $6.14. The stock has a market capitalization of $357.27 million, a P/E ratio of -3.14 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. As a group, analysts forecast that Lexeo Therapeutics will post -1.21 EPS for the current fiscal year.

Insider Activity

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the sale, the insider owned 82,194 shares in the company, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares in the company, valued at $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 62,204 shares of company stock valued at $280,089 in the last 90 days. Corporate insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Spruce Street Capital LP bought a new stake in shares of Lexeo Therapeutics during the fourth quarter worth approximately $1,738,000. Avoro Capital Advisors LLC bought a new position in Lexeo Therapeutics in the fourth quarter valued at approximately $32,769,000. 683 Capital Management LLC boosted its stake in Lexeo Therapeutics by 21.4% in the fourth quarter. 683 Capital Management LLC now owns 1,120,000 shares of the company’s stock valued at $11,122,000 after acquiring an additional 197,338 shares during the last quarter. Bleakley Financial Group LLC acquired a new stake in Lexeo Therapeutics during the 1st quarter worth $275,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at $37,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.